Is Lyra Therapeutics Inc (LYRA) overvalued? · rev $1.5M
Lyra Therapeutics Inc (LYRA) is a biotechnology company listed on US.
This page asks whether Lyra Therapeutics Inc (LYRA) looks expensive on cached numbers — not a short thesis.
Latest reported LYRA revenue for 2024-12-31 was $1.5M. Net income was -$93.4M. Revenue was down 1.5% from 2023-12-31 to 2024-12-31. LYRA currently screens at market cap $14.4M.
LYRA currently screens at market cap $14.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LYRA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LYRA stock page for the full model, not this heading.
Not investment advice.